Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
about
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Gemcitabine-erlotinib versus g ...... anish TTD Collaborative Group.
@en
type
label
Gemcitabine-erlotinib versus g ...... anish TTD Collaborative Group.
@en
prefLabel
Gemcitabine-erlotinib versus g ...... anish TTD Collaborative Group.
@en
P2093
P50
P1476
Gemcitabine-erlotinib versus g ...... anish TTD Collaborative Group.
@en
P2093
Alberto Sáenz
Aleydis Pisa
Alicia Hurtado
Antonio Irigoyen
Enrique Aranda
Esther Falcó
Esther Martínez Ortega
Eva Ma Fernández Parra
Fernando Rivera
Gema Pulido
P356
10.1016/J.EJCA.2016.12.032
P577
2017-02-17T00:00:00Z